OneTest for Cancer Premium
At homeFrom $345 · 20/20 BioLabs
Protein-biomarker multi-cancer early detection, scored by AI
At-home multi-cancer blood test using protein tumor markers and AI scoring for annual risk tracking
OneTest for Cancer is an at-home multi-cancer blood test from 20/20 BioLabs. Instead of reading circulating tumor DNA, it measures established protein tumor markers such as AFP, CEA, CA 19-9, Cyfra 21-1, PSA, CA125, and CA 15-3 on Roche IVD assays, then applies AI scoring to the biomarker pattern. Standard returns one overall risk score across 20+ cancer types; Premium adds individual risk readouts for eight common cancers. Results arrive through an online portal within 14 days and are intended to add another signal alongside standard cancer screening.
A licensed healthcare provider reviews the health questionnaire and authorizes the test before the kit ships. You can use your own physician at no OneTest charge, or add OneTest's $20 telemedicine authorization. The report is physician-reviewed when issued, but follow-up on elevated scores is intended to happen with your own doctor or care team.
The test turns a protein-biomarker panel into a trendable cancer-risk score. Samples run in 20/20 BioLabs' CAP-accredited, CLIA-licensed lab, then the biomarker pattern is scored against an algorithm trained on roughly 28,000 asymptomatic adults followed for 12 years at Chang Gung Medical Hospital. The output is a 1-30 score tied to one-year cancer incidence, giving users and their clinicians a repeatable number to compare year over year.
OneTest does not replace guideline-based screening such as colonoscopy, mammography, low-dose CT, or Pap testing. It is not designed for active cancer symptoms, current treatment, or recurrence monitoring. Follow-up imaging, biopsies, specialist visits, and downstream clinical care are not included in the test fee. Collection and telemedicine authorization are also separate checkout line items unless your own physician handles authorization.
Individual biomarkers are measured on Roche Cobas e411 immunoassay analyzers using Roche FDA-approved IVD detection kits. OneTest then evaluates the full biomarker pattern with an AI algorithm trained on real-world data from roughly 28,000 asymptomatic individuals followed for 12 years at Chang Gung Medical Hospital in Taiwan, later expanded with a 160,000-person Chinese hospital dataset. The result is a 1-30 risk score calibrated to observed one-year cancer incidence among people with similar biomarker patterns.
The $199 Standard tier covers the lab assay: 7 protein biomarkers (5 for men, 6 for women), the composite AI risk score for 20+ cancer types, online portal access, and year-over-year result tracking. Collection is separate: $39 for at-home capillary self-collection or $55 for a partner-clinic draw. Telemedicine authorization is $20 unless your own physician signs the order.
7 biomarkers
7 cancer biomarkers (5 male / 6 female), overall cancer risk score for 20+ cancer types, AI-powered analysis, online portal access, results within 14 days
12 biomarkers
All Standard biomarkers plus 5 inflammatory markers (12 total), individual risk assessment for 8 common cancer types, enhanced detection sensitivity, online portal access, results within 14 days
Prices checked 4 Apr 2026
Pick Standard or Premium, answer the health questionnaire, and route medical authorization through your own physician or OneTest's $20 telemedicine authorization.
FedEx delivers the kit. Collect at home with the $39 capillary kit, or choose a $55 draw through a My One Medical Source or AnyLabTestNow partner clinic. No fasting is required. Ship back promptly: Standard samples must reach the lab within 72 hours, and Premium samples within 48 hours.
Within 14 days, the portal shows each biomarker value, the 1-30 risk score, and the Low, Mild, or Moderate tier. Reports are physician-reviewed when issued and are designed to be shared with your own doctor for any needed follow-up.
Availability checked April 2026
Directory listings are for informational purposes only. Inclusion does not constitute endorsement. Verify credentials and qualifications independently.